Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study

被引：0
|
作者：
Maher, Keri Renee
Schafer, Danielle
Schaar, Dale
Sabo, Roy
Bandyopadhyay, Dipankar
Grant, Steven
机构：
[1] VCU Massey Canc Ctr, Richmond, VA USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[3] Virginia Commonwealth Univ, Richmond, VA USA
[4] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19015
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia
    Isam Abdel-Karim
    William K. Plunkett
    Susan O’Brien
    Francis Giles
    Deborah Thomas
    Stefan Faderl
    Farhad Ravandi
    Mary Beth Rios
    Min Du
    Karen B. Schneck
    Victor J. Chen
    Boris K. Lin
    Steven J. Nicol
    Hagop M. Kantarjian
    Investigational New Drugs, 2011, 29 : 323 - 331
  • [42] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [43] A MULTICENTER PHASE I-II STUDY OF TOSEDOSTAT IN THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA
    Ossenkoppele, G.
    Hooftman, W.
    Zweegman, S.
    Davies, E.
    Morgan, G.
    Mueller-Tidow, C.
    Krug, U.
    Duhrsen, U.
    Burnett, A.
    Jenkins, C.
    Zachee, P.
    Dierickx, D.
    Lowenberg, B.
    Sonneveld, P.
    Hooftman, L.
    Richardson, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 429 - 429
  • [44] Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Winer, Eric S.
    Garcia, Jacqueline S.
    Stone, Richard M.
    Wadleigh, Martha
    Luskin, Marlise R.
    Stahl, Maximilian
    Chen, Evan C.
    Leonard, Rebecca
    Noyes, Alexis
    Galinsky, Ilene
    Deshpande, Rashmi
    Borderies, Pascal
    O'Neill, Vincent
    DeAngelo, Daniel J.
    BLOOD, 2023, 142
  • [45] TRIAL IN PROGRESS: A PHASE 1B STUDY OF ALRIZOMADLIN, ALONE OR PLUS 5-AZACITIDINE OR CYTARABINE, IN PTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND RELAPSED HIGHER-RISK MYELODYSPLASTIC SYNDROME
    Zhai, Yifan
    Wang, Jianxiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A478 - A478
  • [46] A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
    Cogle, Christopher R.
    Gonzalez, Andres
    Pettiford, Leslie
    Meacham, Amy
    Wise, Elizabeth
    Norkin, Maxim
    Chaplin, David
    Balkissoon, Jai
    Hsu, Jack W.
    Brown, Randy A.
    Hiemenz, John W.
    Wingard, John R.
    BLOOD, 2012, 120 (21)
  • [47] A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
    Turner, Daniel
    Gonzalez, Andres
    Pettiford, Leslie
    Meacham, Amy
    Wise, Elizabeth
    Bosse, Raphael C.
    Chaplin, Dai
    Hsu, Jack W.
    Brown, Randy A.
    Hiemenz, John W.
    Norkin, Maxim
    Wingard, John R.
    Cogle, Christopher R.
    BLOOD, 2013, 122 (21)
  • [48] A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
    Kirschbaum, Mark H.
    Foon, Kenneth A.
    Frankel, Paul
    Ruel, Christopher
    Pulone, Bernadette
    Tuscano, Joseph M.
    Newman, Edward M.
    LEUKEMIA & LYMPHOMA, 2014, 55 (10) : 2301 - 2304
  • [49] Phase II study of Mylotarg plus Troxatyl in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
    Giles, FJ
    Garcia-Manero, G
    O'Brien, S
    Estey, E
    Kantarjian, H
    BLOOD, 2001, 98 (11) : 212B - 212B
  • [50] Phase I Study of Bortezomib Combined with Lenalidomide for Relapsed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Following Hematopoietic Cell Transplantation
    Brunner, Andrew M.
    Blonquist, Traci M.
    McMasters, Malgorzata
    Hobbs, Gabriela S.
    McAfee, Steven L.
    Rosenblatt, Jacalyn
    Amrein, Philip C.
    El-Jawahri, Areej
    Connolly, Christine
    Ramos, Aura
    Mikami, Kaleb
    Logan, Emma
    Dey, Bimalangshu R.
    Spitzer, Thomas
    Avigan, David E.
    Fathi, Amir T.
    Chen, Yi-Bin
    Ballen, Karen
    BLOOD, 2017, 130
12345